Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.

Leukemia research - 1 Oct 2014

Huang Bin-Tao, Zeng Qing-Chun, Zhao Wei-Hong, Li Bing-Sheng, Chen Rui-Lin

Abstract excerpt

OBJECTIVE: This open-label, prospective, observational study aimed to evaluate treatment response, efficacy therapy and safety to IFN α-2b for the essential thrombocythemia (ET) and polycythemia vera (PV) with JAK2V617F positive mutation. METHOD: A total of 123 ET patients received IFNα-2b therapy with JAK2V617F positive or negative mutation; and 136 PV patients with JAK2V617F(+) received IFNα-2b or hydroxyurea...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hydroxyurea
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon alpha-2

Share to Janus Kinase 2

Share to Kaplan-Meier Estimate

Share to Polycythemia Vera

Share to Recombinant Proteins

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 25069759
DOI: 10.1016/j.leukres.2014.06.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.PMID 25069759Read ↗

Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis.Semantic proximity Read ↗

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study.Semantic proximity Read ↗

Polycythemia Vera: Rapid Evidence Review.Semantic proximity Read ↗

Pegylated interferon: the who, why, and howSemantic proximity Read ↗

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

[Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].Semantic proximity Read ↗

Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.Semantic proximity Read ↗

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?Semantic proximity Read ↗

Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.Semantic proximity Read ↗

How I treat polycythemia vera.Semantic proximity Read ↗

Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.